Azstarys is a prescription medication approved for the treatment of attention-deficit/hyperactivity disorder (ADHD) in patients aged 13 years and older [1]. It is classified as a Schedule IV controlled substance, indicating it has a potential for abuse [2].
How does Azstarys work?
Azstarys contains two active ingredients: serdexymethylphenidate and dexmethylphenidate [1]. Serdexmethylphenidate is a prodrug that is converted in the body to dexmethylphenidate [1]. Dexmethylphenidate is a central nervous system (CNS) stimulant that is thought to work by increasing the levels of certain neurotransmitters, specifically norepinephrine and dopamine, in the brain [1]. By affecting these neurotransmitters, it can help improve focus and attention and reduce impulsivity and hyperactivity associated with ADHD [1].
Is Azstarys a stimulant medication?
Yes, Azstarys is considered a stimulant medication [1]. Its active ingredients, serdexmethylphenidate and dexmethylphenidate, are chemically related to methylphenidate, which is a common stimulant used to treat ADHD [3].
What are the side effects of Azstarys?
Common side effects associated with Azstarys include decreased appetite, insomnia, weight loss, nausea, vomiting, and irritability [1]. Serious side effects can include cardiovascular problems, psychiatric issues such as new or worsened behavioral or thought disturbances, and circulation problems in the fingers and toes [1].
When does the patent for Azstarys expire?
The patent information for Azstarys, including expiry dates, can be found on DrugPatentWatch.com [4]. Companies often seek to challenge existing patents to facilitate the entry of generic versions of medications [4].
Who makes Azstarys?
Azstarys is manufactured by Corium, Inc. [1].